Literature DB >> 6342641

Antihypertensive effect of propranolol at rest and during exercise.

F H Leenen, P Boer, E J Dorhout Mees.   

Abstract

In eight patients with normal-renin, moderate hypertension, the antihypertensive effects of increasing doses of propranolol (80, 160, 320 and, in three patients, 640 mg/day, each dose for 2 weeks) were evaluated at rest and during exercise in relation to the degree of beta-adrenoceptor blockade induced. A significant decrease (11 +/- 4 mm Hg) in systolic blood pressure was found after propranolol 80 mg/day. Systolic blood pressure showed a fall of 16 +/- 4 mm Hg after 160 mg/day, but no further decrease was measured at higher doses. Diastolic blood pressure showed a significant drop (by 9 +/- 3 mm Hg) after propranolol 80 mg/day; a decrease by 12 +/- 3 mm Hg after propranolol 160 mg/day, but no further decreases at higher doses. PRA and the rise of systolic blood pressure during bicycle exercise were suppressed to a similar extent by propranolol 80 ng and the higher doses. At 80 mg daily exercise tachycardia was reduced by 18%, at 160 mg by 28%, and at the 2 higher doses by 32%. These results suggest that relatively low doses of propranolol (80-160 mg daily) induce most of the antihypertensive effect of propranolol not only at rest but also during exercise. Complete cardiac chronotropic beta-adrenoceptor blockade may not be necessary for the full hypotensive effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342641      PMCID: PMC1427777          DOI: 10.1111/j.1365-2125.1983.tb01511.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Plasma concentrations and the time-course of beta blockade due to propranolol.

Authors:  D G McDevitt; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

2.  Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men.

Authors:  F H Leenen; C H Coenen; M Zonderland; A H Maas
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

3.  The predictable relationship between plasma levels and dose during chronic propranolol therapy.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1978-12       Impact factor: 6.875

4.  Propranolol in hypertension: a dose-response study.

Authors:  D B Galloway; S C Glover; W G Hendry; A W Logie; J C Petrie; M C Smith; J A Lewis; W T Simpson
Journal:  Br Med J       Date:  1976-07-17

5.  Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension.

Authors:  J W Hollifield; K Sherman; R V Zwagg; D G Shand
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

6.  Effects of propranolol on development and maintanance of severe renal hypertension in rats.

Authors:  F H Leenen; E W Ackerman
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 Nov-Dec       Impact factor: 2.557

7.  Sodium intake and the effects of isoproterenol and exercise on plasma renin in man.

Authors:  F H Leenen; P Boer; G G Geyskes
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1978-12

8.  Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.

Authors:  M Esler; A Zweifler; O Randall; V DeQuattro
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

9.  Propranolol in the control of blood pressure: a dose-response study.

Authors:  M J Serlin; M L Orme; N S Baber; R G Sibeon; E Laws; A Breckenridge
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

10.  Hypotensive and renin-suppressing activities of propranolol in hypertensive patients.

Authors:  G Leonetti; G Mayer; A Morganti; L Terzoli; A Zanchetti; G Bianchetti; E Di Salle; P L Morselli; C A Chidsey
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06
  10 in total
  1 in total

Review 1.  A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.

Authors:  J F Waterfall
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.